Report Detail

Request for Sample of this report

Other Global Chronic Myeloid Leukemia (CML) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM3855006
    • |
  • 02 August, 2024
    • |
  • Global
    • |
  • 110 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

According to our (Global Info Research) latest study, the global Chronic Myeloid Leukemia (CML) Treatment market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Chronic myeloid leukaemia (CML) is a type cancer that affects the blood and bone marrow.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Chronic Myeloid Leukemia (CML) Treatment industry chain, the market status of Hospitals (Targeted Therapy, Chemotherapy), Clinic (Targeted Therapy, Chemotherapy), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Chronic Myeloid Leukemia (CML) Treatment.
Regionally, the report analyzes the Chronic Myeloid Leukemia (CML) Treatment markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Chronic Myeloid Leukemia (CML) Treatment market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Chronic Myeloid Leukemia (CML) Treatment market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Chronic Myeloid Leukemia (CML) Treatment industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Targeted Therapy, Chemotherapy).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Chronic Myeloid Leukemia (CML) Treatment market.
Regional Analysis: The report involves examining the Chronic Myeloid Leukemia (CML) Treatment market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Chronic Myeloid Leukemia (CML) Treatment market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Chronic Myeloid Leukemia (CML) Treatment:
Company Analysis: Report covers individual Chronic Myeloid Leukemia (CML) Treatment players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Chronic Myeloid Leukemia (CML) Treatment This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Clinic).
Technology Analysis: Report covers specific technologies relevant to Chronic Myeloid Leukemia (CML) Treatment. It assesses the current state, advancements, and potential future developments in Chronic Myeloid Leukemia (CML) Treatment areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Chronic Myeloid Leukemia (CML) Treatment market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Chronic Myeloid Leukemia (CML) Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
Market segment by Application
Hospitals
Clinic
Others
Market segment by players, this report covers
Novartis AG
Bristol-Myers Squibb
Teva Pharmaceuticals Industries Ltd.
ARIAD Pharmaceuticals, Inc.
Pfizer, Inc.
Hospira, Inc.
Prism Pharmaceuticals
Incyte Corporation
Bio-Path Holdings
Stragen Pharma SA
Otsuka Pharmaceutical Co., Ltd.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Chronic Myeloid Leukemia (CML) Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Chronic Myeloid Leukemia (CML) Treatment, with revenue, gross margin and global market share of Chronic Myeloid Leukemia (CML) Treatment from 2019 to 2024.
Chapter 3, the Chronic Myeloid Leukemia (CML) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Chronic Myeloid Leukemia (CML) Treatment market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Chronic Myeloid Leukemia (CML) Treatment.
Chapter 13, to describe Chronic Myeloid Leukemia (CML) Treatment research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Chronic Myeloid Leukemia (CML) Treatment
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Chronic Myeloid Leukemia (CML) Treatment by Type
    • 1.3.1 Overview: Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Chronic Myeloid Leukemia (CML) Treatment Consumption Value Market Share by Type in 2023
    • 1.3.3 Targeted Therapy
    • 1.3.4 Chemotherapy
    • 1.3.5 Radiation Therapy
    • 1.3.6 Splenectomy
    • 1.3.7 Stem Cell Transplant
  • 1.4 Global Chronic Myeloid Leukemia (CML) Treatment Market by Application
    • 1.4.1 Overview: Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospitals
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Global Chronic Myeloid Leukemia (CML) Treatment Market Size & Forecast
  • 1.6 Global Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast by Region
    • 1.6.1 Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Region, (2019-2030)
    • 1.6.3 North America Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2019-2030)
    • 1.6.6 South America Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Novartis AG
    • 2.1.1 Novartis AG Details
    • 2.1.2 Novartis AG Major Business
    • 2.1.3 Novartis AG Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.1.4 Novartis AG Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Novartis AG Recent Developments and Future Plans
  • 2.2 Bristol-Myers Squibb
    • 2.2.1 Bristol-Myers Squibb Details
    • 2.2.2 Bristol-Myers Squibb Major Business
    • 2.2.3 Bristol-Myers Squibb Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.2.4 Bristol-Myers Squibb Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.3 Teva Pharmaceuticals Industries Ltd.
    • 2.3.1 Teva Pharmaceuticals Industries Ltd. Details
    • 2.3.2 Teva Pharmaceuticals Industries Ltd. Major Business
    • 2.3.3 Teva Pharmaceuticals Industries Ltd. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.3.4 Teva Pharmaceuticals Industries Ltd. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Teva Pharmaceuticals Industries Ltd. Recent Developments and Future Plans
  • 2.4 ARIAD Pharmaceuticals, Inc.
    • 2.4.1 ARIAD Pharmaceuticals, Inc. Details
    • 2.4.2 ARIAD Pharmaceuticals, Inc. Major Business
    • 2.4.3 ARIAD Pharmaceuticals, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.4.4 ARIAD Pharmaceuticals, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 ARIAD Pharmaceuticals, Inc. Recent Developments and Future Plans
  • 2.5 Pfizer, Inc.
    • 2.5.1 Pfizer, Inc. Details
    • 2.5.2 Pfizer, Inc. Major Business
    • 2.5.3 Pfizer, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.5.4 Pfizer, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Pfizer, Inc. Recent Developments and Future Plans
  • 2.6 Hospira, Inc.
    • 2.6.1 Hospira, Inc. Details
    • 2.6.2 Hospira, Inc. Major Business
    • 2.6.3 Hospira, Inc. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.6.4 Hospira, Inc. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Hospira, Inc. Recent Developments and Future Plans
  • 2.7 Prism Pharmaceuticals
    • 2.7.1 Prism Pharmaceuticals Details
    • 2.7.2 Prism Pharmaceuticals Major Business
    • 2.7.3 Prism Pharmaceuticals Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.7.4 Prism Pharmaceuticals Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Prism Pharmaceuticals Recent Developments and Future Plans
  • 2.8 Incyte Corporation
    • 2.8.1 Incyte Corporation Details
    • 2.8.2 Incyte Corporation Major Business
    • 2.8.3 Incyte Corporation Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.8.4 Incyte Corporation Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Incyte Corporation Recent Developments and Future Plans
  • 2.9 Bio-Path Holdings
    • 2.9.1 Bio-Path Holdings Details
    • 2.9.2 Bio-Path Holdings Major Business
    • 2.9.3 Bio-Path Holdings Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.9.4 Bio-Path Holdings Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Bio-Path Holdings Recent Developments and Future Plans
  • 2.10 Stragen Pharma SA
    • 2.10.1 Stragen Pharma SA Details
    • 2.10.2 Stragen Pharma SA Major Business
    • 2.10.3 Stragen Pharma SA Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.10.4 Stragen Pharma SA Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Stragen Pharma SA Recent Developments and Future Plans
  • 2.11 Otsuka Pharmaceutical Co., Ltd.
    • 2.11.1 Otsuka Pharmaceutical Co., Ltd. Details
    • 2.11.2 Otsuka Pharmaceutical Co., Ltd. Major Business
    • 2.11.3 Otsuka Pharmaceutical Co., Ltd. Chronic Myeloid Leukemia (CML) Treatment Product and Solutions
    • 2.11.4 Otsuka Pharmaceutical Co., Ltd. Chronic Myeloid Leukemia (CML) Treatment Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Chronic Myeloid Leukemia (CML) Treatment Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Chronic Myeloid Leukemia (CML) Treatment by Company Revenue
    • 3.2.2 Top 3 Chronic Myeloid Leukemia (CML) Treatment Players Market Share in 2023
    • 3.2.3 Top 6 Chronic Myeloid Leukemia (CML) Treatment Players Market Share in 2023
  • 3.3 Chronic Myeloid Leukemia (CML) Treatment Market: Overall Company Footprint Analysis
    • 3.3.1 Chronic Myeloid Leukemia (CML) Treatment Market: Region Footprint
    • 3.3.2 Chronic Myeloid Leukemia (CML) Treatment Market: Company Product Type Footprint
    • 3.3.3 Chronic Myeloid Leukemia (CML) Treatment Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Chronic Myeloid Leukemia (CML) Treatment Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Chronic Myeloid Leukemia (CML) Treatment Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Chronic Myeloid Leukemia (CML) Treatment Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Chronic Myeloid Leukemia (CML) Treatment Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Type (2019-2030)
  • 6.2 North America Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Application (2019-2030)
  • 6.3 North America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
    • 6.3.1 North America Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Country (2019-2030)
    • 6.3.2 United States Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Type (2019-2030)
  • 7.2 Europe Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Application (2019-2030)
  • 7.3 Europe Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
    • 7.3.1 Europe Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 7.3.3 France Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Size by Region
    • 8.3.1 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Region (2019-2030)
    • 8.3.2 China Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 8.3.5 India Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Type (2019-2030)
  • 9.2 South America Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Application (2019-2030)
  • 9.3 South America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
    • 9.3.1 South America Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Market Size by Country
    • 10.3.1 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Chronic Myeloid Leukemia (CML) Treatment Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Chronic Myeloid Leukemia (CML) Treatment Market Drivers
  • 11.2 Chronic Myeloid Leukemia (CML) Treatment Market Restraints
  • 11.3 Chronic Myeloid Leukemia (CML) Treatment Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Chronic Myeloid Leukemia (CML) Treatment Industry Chain
  • 12.2 Chronic Myeloid Leukemia (CML) Treatment Upstream Analysis
  • 12.3 Chronic Myeloid Leukemia (CML) Treatment Midstream Analysis
  • 12.4 Chronic Myeloid Leukemia (CML) Treatment Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Chronic Myeloid Leukemia (CML) Treatment. Industry analysis & Market Report on Chronic Myeloid Leukemia (CML) Treatment is a syndicated market report, published as Global Chronic Myeloid Leukemia (CML) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Chronic Myeloid Leukemia (CML) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo